HeartBeam Inc. (NASDAQ: BEAT) announced that its management team will participate in several investor and industry conferences throughout March 2026. The company's executives will engage with the investment community and medical professionals while demonstrating its cardiac monitoring technology.
CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16. During this event, they will meet with institutional and retail investors to discuss the company's progress and future plans. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel discussion focused on technologies advancing healthy aging.
Additionally, Eno, Founder and President Dr. Branislav Vajdic, and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference on March 28-30. At this premier cardiology event, the company will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners.
This series of conference appearances is significant because HeartBeam is developing technology that could transform cardiac care delivery. The company is creating the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing these signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is located, delivering actionable heart intelligence outside traditional medical facilities.
The potential impact of this technology is substantial for both patients and healthcare systems. Physicians could use HeartBeam's system to identify cardiac health trends and acute conditions while directing patients to appropriate care without requiring hospital visits. This approach could redefine cardiac health management by enabling continuous monitoring in home settings rather than clinical environments.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology enablement. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
For details on the intended use of HeartBeam's technology, refer to the company's Cleared Indications for Use at https://www.heartbeam.com/indications. The company's conference participation represents an opportunity to advance adoption of technology that could make cardiac monitoring more accessible and convenient for patients while potentially reducing healthcare costs associated with traditional monitoring methods.
